SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer
Investegate announcements from ProLynx LLC, ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic